User: Guest  Login
Title:

A new galenic formulation of selegiline (Xilopae) in the treatment of Parkinson disease

Document type:
Article
Author(s):
Müller, T; Glass, J; Müller, D; Link, A; Schenk, C; Rammes, G
Abstract:
Selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B). Selegiline is looked upon as a putative progression of Parkinson's disease (PD) delaying compound due to its in preclinical research proven neuroprotective modes of action. Xilopar(R) is a new formulation of selegiline, which facilitates absorption in the mouth and thus avoids hepatic first-pass metabolism. Intake of 1.25 mg Xilopar(R) provides similar pharmacokinetic plasma behaviour corresponding to oral admin...     »
Journal title abbreviation:
Aktuelle Neurologie
Year:
2004
Journal volume:
31
Journal issue:
7
Pages contribution:
347-352
Language:
eng
Print-ISSN:
0302-4350
TUM Institution:
Klinik für Anästhesiologie (DHM)
 BibTeX